Another challenge is how to use CSF AD biomarkers to attempt and reduce the confound of preclinical AD, and we opted to use tau/Aβ1–42 because it is now generally considered the most reliable CSF biomarker of AD [26]. The gene discussed is MAPT; the disease is Alzheimer disease.